Lumina Pharmaceuticals announces FDA clearance of IND application for CM500
Novel, first-in-class radiopharmaceutical targeting a hallmark of the solid tumor microenvironment December 22, 2025, Boston, MA – Lumina Pharmaceuticals, a clinical-stage radiopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CM500. Lumina will proceed with a Phase 0 clinical study of [68Ga]CM500 and […]
Lumina Pharmaceuticals Announces Hire of Eric Hoffman as Chief Business Officer
December 1, 2025: Lumina Pharmaceuticals, a clinical stage company developing radiopharmaceuticals, announced today that industry expert Eric S. Hoffman, Ph.D., will join the company as Chief Business Officer. In this role, Dr. Hoffman will be responsible for leading business development, strategic partnerships, and corporate strategy initiatives to advance the company’s pipeline and commercial objectives. Hoffman […]
Science Translational Medicine Publishes Article Outlining Development of a Fibrin-Targeted Theranostic for Gastric Cancer
In the publication, the authors describe a theranostic approach for targeting fibrin deposition in the tumor extracellular matrix first with a copper-64 labeled, fibrin-specific positron emission tomography (PET) imaging probe and then with a yttrium-90 labeled fibrin-specific therapeutic to treat gastric cancer.